In this segment of his Q&A interview, Charles Lynde, MD, reviews upadacitinib's safety profile in the UP-AA trials and how it could reshape alopecia areata care.
Charles Lynde, MD
Advertisement
Charles Lynde, MD, is an associate professor in the Department of Medicine at the University of Toronto. He is the also Chief Medical Director of Lynde Institute for Dermatology and Lynderm Research.
Articles by Charles Lynde, MD
In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
4
ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity
5